Skip to main content

New Government Commission Could Streamline Diabetes Care


July 30, 2012 — Two US senators have introduced an act that would ensure a thorough review of the US government's approach to diabetes care, an effort experts hope will ultimately slow the pace of this burgeoning epidemic. Several major medical associations were quick to applaud the bipartisan effort, which came out of the Senate Diabetes Caucus and its cochairs, senators Jeanne Shaheen (D-NH) and Susan Collins (R-Maine).
If approved, the National Diabetes Clinical Care Commission Act will create a public–private sector commission to recommend improvements to care.
"This is a fabulous idea when it comes to diabetes," Joan Salge Blake, RD, LDN, a spokesperson for the Academy of Nutrition and Dietetics, said to Medscape Medical News. "Prevention is key, it's absolutely key. Diabetes is the number 7 killer of Americans, and it's something we have a good chance of preventing. But more and more Americans are getting diabetes, and so many issues go along with it, kidney problems, eyesight issues, so many other health issues."
The Juvenile Diabetes Research Foundation (JDRF) also supports the commission formation. "As [the] national cost of diabetes [continues] to rise, it makes sense to ensure federal resources for diabetes care are leveraged most effectively and efforts are well coordinated so that patients receive the best possible care," Cynthia Rice, vice president, government relations, for JDRF said in an email to Medscape Medical News.
"There is a recognition in the diabetes community that continuation of the status quo is unacceptable," Alan Garber, MD, PhD, president of the American Association of Clinical Endocrinologists (AACE), said in a news release. "Doing nothing or even doing more of the same will not reverse the arc of worsening diabetes prevalence and complications which will ultimately overwhelm the entire healthcare system with devastating numbers of patients with this disease alone."
The National Diabetes Clinical Care Commission Act was introduced in September in the US House of Representatives and today has 26 cosponsors, including members of the Physician Caucus.
Under the Senate bill, the National Diabetes Clinical Care Commission will include healthcare professionals who work with patients with diabetes, as well as patient advocates and representatives of federal agencies involved with diabetes care. The group is to make recommendations to the US Secretary of Health and Human Services and to Congress.
The act is endorsed by the major diabetes organizations, including the Pediatric Endocrine Society, the Endocrine Society, the American Academy of Ophthalmology, and the American Diabetes Association, in addition to the AACE and JDRF.
The number of patients with type 2 diabetes in the United States has been growing unchecked in recent decades, roughly at pace with increasing obesity. The US Centers for Disease Control and Prevention (CDC) predicts that 1 in 3 children born in 2000 will develop the disease in their lifetime. Some 26 million Americans have diabetes today, the CDC says, and another 79 million have prediabetes, which greatly predisposes them to developing the disease. In the last 3 years alone, the number of people diagnosed with diabetes jumped by 2 million, and the number with prediabetes grew by 22 million, the CDC says.
In addition, data from the CDC and National Institutes of Health show that incidence of type 1 diabetes also is rising rapidly among youth, with a 23% increase from 2001 to 2009, JDRF's Rice wrote in her email.
Diabetes care costs the United States $174 billion per year, including a third of all Medicare spending.
"AACE believes the National Diabetes Clinical Care Commission is a significant first step in the nation's battle against diabetes and its consequences," Dr. Garber said in a news release.
 

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more